Roush David J, Lu Yuefeng
BioPurification Development, Merck Research Laboratories, P.O. Box 2000, Mailstop RY805S-100, Rahway, New Jersey 07065, USA.
Biotechnol Prog. 2008 May-Jun;24(3):488-95. doi: 10.1021/bp070414x. Epub 2008 Apr 15.
Significant and continual improvements in upstream processing for biologics have resulted in challenges for downstream processing, both primary recovery and purification. Given the high cell densities achievable in both microbial and mammalian cell culture processes, primary recovery can be a significant bottleneck in both clinical and commercial manufacturing. The combination of increased product titer and low viability leads to significant relative increases in the levels of process impurities such as lipids, intracellular proteins and nucleic acid versus the product. In addition, cell culture media components such as soy and yeast hydrolysates have been widely applied to achieve the cell culture densities needed for higher titers. Many of the process impurities can be negatively charged at harvest pH and can form colloids during the cell culture and harvest processes. The wide size distribution of these particles and the potential for additional particles to be generated by shear forces within a centrifuge may result in insufficient clarification to prevent fouling of subsequent filters. The other residual process impurities can lead to precipitation and increased turbidity during processing and even interference with the performance of the capturing chromatographic step. Primary recovery also poses significant challenges owing to the necessity to execute in an expedient manner to minimize both product degradation and bioburden concerns. Both microfiltration and centrifugation coupled with depth filtration have been employed successfully as primary recovery processing steps. Advances in the design and application of membrane technology for microfiltration and dead-end filtration have contributed to significant improvements in process performance and integration, in some cases allowing for a combination of multiple unit operations in a given step. Although these advances have increased productivity and reliability, the net result is that optimization of primary recovery processes has become substantially more complicated. Ironically, the application of classical chemical engineering approaches to overcome issues in primary recovery and purification (e.g., turbidity and trace impurity removal) are just recently gaining attention. Some of these techniques (e.g., membrane cascades, pretreatment, precipitation, and the use of affinity tags) are now seen almost as disruptive technologies. This paper will review the current and potential future state of research on primary recovery, including relevant papers presented at the 234th American Chemical Society (ACS) National Meeting in Boston.
生物制品上游加工工艺取得的重大且持续的改进给下游加工带来了挑战,包括初步回收和纯化。鉴于微生物和哺乳动物细胞培养过程中可实现的高细胞密度,初步回收可能成为临床和商业生产中的重大瓶颈。产品滴度增加和细胞活力降低共同导致了诸如脂质、细胞内蛋白质和核酸等工艺杂质相对于产品的水平显著相对增加。此外,大豆和酵母水解物等细胞培养基成分已被广泛应用,以实现更高滴度所需的细胞培养密度。许多工艺杂质在收获时的pH值下可能带负电荷,并在细胞培养和收获过程中形成胶体。这些颗粒的宽尺寸分布以及离心机内剪切力可能产生额外颗粒的可能性,可能导致澄清不足,无法防止后续过滤器的污染。其他残留的工艺杂质可能导致加工过程中沉淀增加和浊度升高,甚至干扰捕获色谱步骤的性能。初步回收还带来了重大挑战,因为必须以权宜之计进行操作,以尽量减少产品降解和生物负荷问题。微滤以及与深层过滤相结合的离心法都已成功用作初步回收加工步骤。微滤和死端过滤膜技术在设计和应用方面的进展有助于显著提高工艺性能和集成度,在某些情况下,允许在给定步骤中组合多个单元操作。尽管这些进展提高了生产率和可靠性,但最终结果是初步回收工艺的优化变得更加复杂。具有讽刺意味的是,应用经典化学工程方法来克服初步回收和纯化中的问题(例如,浊度和痕量杂质去除)直到最近才受到关注。其中一些技术(例如,膜级联、预处理、沉淀以及亲和标签的使用)现在几乎被视为颠覆性技术。本文将回顾初步回收的当前和潜在未来研究状况,包括在波士顿举行的第234届美国化学学会(ACS)全国会议上发表的相关论文。